These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

25 related articles for article (PubMed ID: 2128721)

  • 1. Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice.
    Castagne V; Bonhomme-Faivre L; Urien S; Ben Reguiga M; Soursac M; Gimenez F; Farinotti R
    Drug Metab Dispos; 2004 Feb; 32(2):168-71. PubMed ID: 14744937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of exenatide on the steady-state pharmacokinetics of digoxin.
    Kothare PA; Soon DK; Linnebjerg H; Park S; Chan C; Yeo A; Lim M; Mace KF; Wise SD
    J Clin Pharmacol; 2005 Sep; 45(9):1032-7. PubMed ID: 16100297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic investigation of digoxin in Japanese neonates.
    Yukawa E; Akiyama K; Suematsu F; Yukawa M; Minemoto M
    J Clin Pharm Ther; 2007 Aug; 32(4):381-6. PubMed ID: 17635340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The dosage of cardiotonic agents in infants as a function of their serum levels and pharmacokinetics].
    Nanulescu M; Leucuţa S; Bucerzan C; Samir A; Szabó P
    Rev Pediatr Obstet Ginecol Pediatr; 1990; 39(1):89-94. PubMed ID: 2128721
    [No Abstract]   [Full Text] [Related]  

  • 5. The serum digoxin concentration: ten questions to ask.
    Cauffield JS; Gums JG; Grauer K
    Am Fam Physician; 1997 Aug; 56(2):495-503, 509-10. PubMed ID: 9262530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Digoxin].
    Yamamoto K
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():403-5. PubMed ID: 15658349
    [No Abstract]   [Full Text] [Related]  

  • 7. [Digoxin].
    Kotaki H; Iga T
    Nihon Rinsho; 1995 Feb; 53 Su Pt 1():950-3. PubMed ID: 8753596
    [No Abstract]   [Full Text] [Related]  

  • 8. Goal-oriented, model-based drug regimens: setting individualized goals for each patient.
    Jelliffe R
    Ther Drug Monit; 2000 Jun; 22(3):325-9. PubMed ID: 10850402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Digoxin].
    Yamamoto K
    Nihon Rinsho; 1999 Sep; 57 Suppl():387-9. PubMed ID: 10543134
    [No Abstract]   [Full Text] [Related]  

  • 10. Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.
    Pillai GC; Mentré F; Steimer JL
    J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):161-83. PubMed ID: 16283536
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.